Related Experiment Video

Updated: Jun 28, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Effects of early losartan therapy on ventricular late potentials in acute myocardial infarction

Dae-Hyeok Kim1, Woong-Gil Choi, Jun Kwan

  • 1Department of Cardiology, Inha University College of Medicine, Incheon, Korea. kdhmd@inha.ac.kr

Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
|November 1, 2008
PubMed

Insights

Early losartan therapy after acute myocardial infarction (AMI) reduced ventricular late potentials (LPs), indicating a potential improvement in arrhythmia substrates. This noninvasive signal-averaged electrocardiogram (SAECG) finding suggests a favorable effect on cardiac electrical stability.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Pharmacology

Background:

  • Ventricular late potentials (LPs) on signal-averaged electrocardiogram (SAECG) predict arrhythmic events post-acute myocardial infarction (AMI).
  • Angiotensin receptor blockers (ARBs) are known to reduce mortality and sudden cardiac death in post-MI patients.

Purpose of the Study:

  • To investigate the impact of early losartan therapy on ventricular LPs in AMI patients.
  • To evaluate losartan's effect on arrhythmogenic substrates using SAECG.

Main Methods:

  • A study involving 97 patients with their first AMI.
  • 48 patients received early losartan therapy; 49 served as a control group.
  • SAECG was performed at admission and on day 14.

Main Results:

  • No significant differences in baseline characteristics or SAECG findings between groups.
  • A significant decrease in LP incidence was observed in the losartan group post-reperfusion.
  • All LP parameters significantly improved in the losartan group by day 14.

Conclusions:

  • Early losartan treatment post-AMI significantly reduced the incidence of ventricular late potentials.
  • Losartan therapy may favorably influence the arrhythmogenic substrates in AMI patients.
Abstract

More Related Videos

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...